Cardio-drug clears hurdle
Vienna – Cardiovascular and inflammatory specialist Fibrex Medical has published positive Phase II results for FX06, a peptide for the treatment of reperfusion injury – damage to heart muscle that results from remedial treatment following a heart attack. 234 patients with acute myocardial infarcts were included in the trial. The data indicated a statistically significant reduction in myocardial necrosis compared to placebo following intravenous application. FX06 is a peptide that binds to the vascular endothelial (VE) cadherin, thereby inhibiting tissue inflammation and injury and preserving endothelial barrier function. These effects are deemed to be important for the prevention of additional damage to the heart.